Patents by Inventor Bettina Van Lengerich

Bettina Van Lengerich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-TREM2 antibodies and methods of use thereof
    Patent number: 12240902
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: March 4, 2025
    Assignee: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh
  • FUSION PROTEINS COMPRISING PROGRANULIN
    Publication number: 20230406898
    Abstract: Provided herein are fusion proteins that comprise progranulin and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Application
    Filed: April 12, 2023
    Publication date: December 21, 2023
    Applicant: Denali Therapeutics Inc.
    Inventors: Gilbert Di Paolo, Todd P. Logan, Kathryn M. Monroe, Ankita Srivastava, Bettina Van Lengerich
  • METHODS FOR TREATING DYSREGULATED LIPID METABOLISM
    Publication number: 20230132366
    Abstract: Certain embodiments described herein provide a method for treating dysregulated lipid metabolism and/or inflammation in a mammal in need thereof, comprising administering to the mammal an effective amount of an agonist anti-triggering receptor expressed on myeloid cells 2 (TREM2) antibody.
    Type: Application
    Filed: November 26, 2019
    Publication date: April 27, 2023
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Giuseppe ASTARITA, Gilbert DI PAOLO, Kai Lin LIN, Kathryn M. MONROE, Alicia A. NUGENT, Bettina VAN LENGERICH
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220177576
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: September 17, 2021
    Publication date: June 9, 2022
    Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis Kariolis, Cathal Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220119522
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: August 16, 2021
    Publication date: April 21, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220073609
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: August 16, 2021
    Publication date: March 10, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh
  • METHODS FOR TREATING DYSREGULATED LIPID METABOLISM
    Publication number: 20220025039
    Abstract: Certain embodiments described herein provide a method for treating dysregulated lipid metabolism and/or inflammation in a mammal in need thereof, comprising administering to the mammal an effective amount of an agonist anti-triggering receptor expressed on myeloid cells 2 (TREM2) antibody.
    Type: Application
    Filed: November 26, 2019
    Publication date: January 27, 2022
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Giuseppe ASTARITA, Gilbert DI PAOLO, Kai Lin LIN, Kathryn M. MONROE, Alicia A. NUGENT, Bettina VAN LENGERICH
  • Anti-TREM2 antibodies and methods of use thereof
    Patent number: 11124567
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: September 21, 2021
    Assignee: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis S. Kariolis, Cathal S. Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
  • FUSION PROTEINS COMPRISING PROGRANULIN
    Publication number: 20210284702
    Abstract: Provided herein are fusion proteins that comprise progranulin and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Application
    Filed: June 18, 2019
    Publication date: September 16, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Gilbert Di Paolo, Todd P. Logan, Kathryn M. Monroe, Ankita Srivastava, Bettina Van Lengerich
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210214438
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: January 15, 2021
    Publication date: July 15, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis S. Kariolis, Cathal S. Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200277373
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody increases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody decreases levels of sTREM2. In some embodiments, the antibody enhances TREM2 activity. In some embodiments, the antibody inhibits TREM2 activity.
    Type: Application
    Filed: September 14, 2018
    Publication date: September 3, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Hang Chen, Gilbert Di Paolo, Rui Hao, Joseph W. Lewcock, Nathan Moerke, Alicia A. Nugent, Rishi Rakhit, Ju Shi, Rinkan Shukla, Ankita Srivastava, Bettina Van Lengerich, Yin Zhang